Table A.5.
Falsification Test on Timing of Patient E-Visit Adoption (Placebo Analysis)
| Full diff-in-diff |
IV |
|||||||
|---|---|---|---|---|---|---|---|---|
| (1) Office | (2) Phone | (3) LDL | (4) HbA1c | (5) Office | (6) Phone | (7) LDL | (8) HbA1c | |
| Patient E-Visit Adoption | 0.003 | 0.003 | 0.006 | 0.001 | 17.260 | 8.291 | 3.414 | 2.627 |
| (0.002) | (0.003) | (0.007) | (0.009) | (35.967) | (18.476) | (9.122) | (3.333) | |
| Patient FEs | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Provider FEs | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Month FEs | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Year FEs | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| R2 | 0.002 | 0.002 | 0.013 | 0.014 | — | — | — | — |
| Patient-months | 5,947,707 | 5,947,707 | 240,605 | 123,230 | 5,947,707 | 5,947,707 | 240,605 | 123,230 |
| Weak id. (KP rk Wald F-stat.) | — | — | — | — | 0.230 | 0.230 | 0.189 | 0.785 |
| Underid. (KP rk LM p-value) | — | — | — | — | 0.228 | 0.228 | 0.664 | 0.379 |
Notes. Patient E-Visit Adoption is randomized across the 62 months of our data for 13.4% of all patients, consistent with the rate of adoption in our sample. The IV analysis continues to use as an instrument the number of e-visits that a patient’s provider conducts with all other patients in a given month. LDL and HbA1c are binary variables that equal 1 if at least one measurement of the relevant outcome is unhealthy in a given month. Sample includes all patient-months except for the month before, month of, and month after placebo e-visit adoption (for this reason, the sample size differs slightly from that in the main analysis). The Wald F-statistic and test of underidentification are based on Kleibergen and Paap (2006). The Stock and Yogo (2005) critical value is 16.38 for the IV estimates to have no more than 10% of the bias of the ordinary least squares estimates. Standard errors in parentheses are robust and two-way clustered at the patient and the provider-month levels.